2011
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
, , Sawcer S, Hellenthal G, Pirinen M, Spencer C, Patsopoulos N, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt S, Edkins S, Gray E, Booth D, Potter S, Goris A, Band G, Oturai A, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D’alfonso S, Blackburn H, Boneschi F, Liddle J, Harbo H, Perez M, Spurkland A, Waller M, Mycko M, Ricketts M, Comabella M, Hammond N, Kockum I, McCann O, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead S, Barcellos L, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini S, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield J, Brassat D, Broadley S, Buck D, Butzkueven H, Capra R, Carroll W, Cavalla P, Celius E, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox M, Cozen W, Cree B, Cross A, Cusi D, Daly M, Davis E, de Bakker P, Debouverie M, D’hooghe M, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant S, Guerini F, Hakonarson H, Hall P, Hamsten A, Hartung H, Heard R, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode A, Kilpatrick T, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott J, Leone M, Leppä V, Liljedahl U, Bomfim I, Lincoln R, Link J, Liu J, Lorentzen Å, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley J, Mentch F, Mero I, Mihalova T, Montalban X, Mottershead J, Myhr K, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach H, Ramsay P, Reunanen M, Reynolds R, Rioux J, Rodegher M, Roesner S, Rubio J, Rückert I, Salvetti M, Salvi E, Santaniello A, Schaefer C, Schreiber S, Schulze C, Scott R, Sellebjerg F, Selmaj K, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman P, Smestad C, Sørensen P, Søndergaard H, Stankovich J, Strange R, Sulonen A, Sundqvist E, Syvänen A, Taddeo F, Taylor B, Blackwell J, Tienari P, Bramon E, Tourbah A, Brown M, Tronczynska E, Casas J, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus H, Wang K, Mathew C, Wason J, Palmer C, Wichmann H, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath R, Yaouanq J, Viswanathan A, Zhang H, Wood N, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg J, Pericak-Vance M, Haines J, Olsson T, Hillert J, Ivinson A, De Jager P, Peltonen L, Stewart G, Hafler D, Hauser S, McVean G, Donnelly P, Compston A. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476: 214-219. PMID: 21833088, PMCID: PMC3182531, DOI: 10.1038/nature10251.Peer-Reviewed Original ResearchMeSH KeywordsAllelesCell DifferentiationEuropeGenetic Predisposition to DiseaseGenome-Wide Association StudyGenome, HumanHLA-A AntigensHLA-DR AntigensHLA-DRB1 ChainsHumansImmunity, CellularMajor Histocompatibility ComplexMultiple SclerosisPolymorphism, Single NucleotideSample SizeT-Lymphocytes, Helper-InducerConceptsCollaborative genome-wide association studiesGenome-wide association studiesNovel susceptibility lociRegions of DNAGenetic architectureAssociation studiesSusceptibility lociDifferentiation of T helper cellsGenetic riskEuropean descentCell-mediated immune mechanismsT helper cellsCentral nervous systemImmune mechanismsLociIntensive studyDNAMultiple sclerosisNervous systemGeneticsNeurodegenerationDiseaseSclerosisDifferentiationCellsIdentification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune disease
Dominguez-Villar M, Baecher-Allan CM, Hafler DA. Identification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune disease. Nature Medicine 2011, 17: 673-675. PMID: 21540856, PMCID: PMC3675886, DOI: 10.1038/nm.2389.Peer-Reviewed Original ResearchConceptsTreg cellsT helper type 1Regulatory T cellsT regulatory (Treg) cellsHelper type 1T helper typeHuman autoimmune diseasesHuman Treg cellsRegulatory cellsIL-12Multiple sclerosisAutoimmune diseasesPeripheral bloodHelper typeT cellsSuppressive activityType 1Functional plasticityConsiderable phenotypicCellsSclerosisIFNDiseaseMiceBlood
1996
Pilot Study of Oral Tolerance to Keyhole Limpet Hemocyanin in Humans.
MATSUI M, HAFLER D, WEINER H. Pilot Study of Oral Tolerance to Keyhole Limpet Hemocyanin in Humans. Annals Of The New York Academy Of Sciences 1996, 778: 398-404. PMID: 8611003, DOI: 10.1111/j.1749-6632.1996.tb21156.x.Peer-Reviewed Original Research
1993
Pathogenesis of Diseases Induced by Human Lymphotropic Virus Type I Infection
Flier J, Underhill L, Hollsberg P, Hafler D. Pathogenesis of Diseases Induced by Human Lymphotropic Virus Type I Infection. New England Journal Of Medicine 1993, 328: 1173-1182. PMID: 8455685, DOI: 10.1056/nejm199304223281608.Peer-Reviewed Original Research
1988
Immunotherapy of multiple sclerosis
Weiner H, Hafler D. Immunotherapy of multiple sclerosis. Annals Of Neurology 1988, 23: 211-222. PMID: 3288084, DOI: 10.1002/ana.410230302.Peer-Reviewed Original ResearchConceptsMultiple sclerosisClinical trialsHelper/inducer cellsOnset of progressionMultiple sclerosis therapyNumber of relapsesPresent treatment modalitiesAntigen-specific cellsActivated T cellsImmune balanceImmunotherapeutic interventionsNonspecific immunosuppressionSclerosis therapyAcute attacksAutoimmune diseasesInducer cellsLymphocyte trafficTreatment modalitiesSuppressor influencesEarly treatmentT cellsEffective treatmentTherapeutic goalsImmunotherapyImmune system
1986
Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis
Johnson D, Hafler D, Fallis R, Lees M, Brady R, Quarles R, Weiner H. Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis. Journal Of Neuroimmunology 1986, 13: 99-108. PMID: 2428837, DOI: 10.1016/0165-5728(86)90053-6.Peer-Reviewed Original ResearchConceptsActive MS patientsMyelin basic proteinPeripheral blood lymphocytesMyelin antigensMS patientsControl subjectsActive MSMultiple sclerosisNeurologic diseaseProteolipid proteinStable multiple sclerosis patientsMean proliferative responseCell-mediated immunityMultiple sclerosis patientsBasic proteinStable MSOND groupSclerosis patientsT8 subsetsBlood lymphocytesLymphocyte stimulationProliferative responseProportion of individualsPatientsAntigen